Skip to main content
. 2021 Jan 21;28(2):626–639. doi: 10.1038/s41418-020-00720-9

Fig. 3. Twelve candidate vaccines currently in Phase III trial: COVID-19 Vaccines based on Spike protein.

Fig. 3

These vaccines are probably the most immunogenic also thanks to the combination with new adjuvants [14]. The exploitation of transgenic plants as producers of Spike protein could allow the production of large quantities of the vaccine at an extremely low cost.